Journal article

Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study

Anja Rudolph, Rebecca Hein, Sara Lindstroem, Lars Beckmann, Sabine Behrens, Jianjun Liu, Hugues Aschard, Manjeet K Bolla, Jean Wang, Therese Truong, Emilie Cordina-Duverger, Florence Menegaux, Thomas Bruening, Volker Harth, Gianluca Severi, Laura Baglietto, Melissa Southey, Stephen J Chanock, Jolanta Lissowska, Jonine D Figueroa Show all

Endocrine - Related Cancer | BIOSCIENTIFICA LTD | Published : 2013

Grants

Awarded by European Community's Seventh Framework Program


Awarded by (COGS), Cancer Research UK


Awarded by National Institutes of Health


Awarded by Post-Cancer GWAS initiative


Awarded by Department of Defence


Awarded by European Union COST program


Awarded by Federal Ministry of Education and Research (BMBF) Germany


Awarded by Deutsche Krebshilfe e.V


Awarded by NIH


Awarded by Specialized Program of Research Excellence (SPORE) in Breast Cancer


Awarded by Australian NHMRC


Awarded by US NIH (National Institute of Health)


Awarded by National Cancer Institute.


Awarded by NHMRC


Awarded by AOCS was provided by the United States Army Medical Research and Materiel Command


Awarded by NATIONAL CANCER INSTITUTE


Awarded by Cancer Research UK


Awarded by The Francis Crick Institute


Awarded by National Breast Cancer Foundation


Funding Acknowledgements

Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Program under grant agreement n degrees 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692), the National Institutes of Health CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065, and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. Meetings of the BCAC have been funded by the European Union COST program (BM0606). D F Easton is a Principal Research Fellow of CR-UK. The CECILE study was funded by the Fondation de France; the French National Institute of Cancer (INCa); The National League against Cancer; the National Agency for Environmental and Occupational Health and Food Safety (ANSES), the National Agency for Research (ANR), and the Association for Research against Cancer (ARC). GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0, and 01KW0114 as well as 01KH0401, 01KH0410, 01KH0411, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The MARIE study was supported by the Deutsche Krebshilfe e.V. (70-2892-BR I), the Hamburg Cancer Society, the German Cancer Research Center and genotype work in part by the Federal Ministry of Education and Research (BMBF) Germany (01KH0402). The MCBCS was supported by the NIH grants (CA122340, CA128978) and a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201). MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. The Nurses' Health Studies are supported by US NIH (National Institute of Health) grants CA65725, CA87969, CA49449, CA67262, CA50385, and 5UO1CA098233. OFBCR was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. kConFab is supported by grants from the National Breast Cancer Foundation, the NHMRC, the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia and the Cancer Foundation of Western Australia. The kConFab Clinical Follow-Up Study was funded by the NHMRC (145684, 288704, 454508). Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command (DAMD17-01-1-0729), the Cancer Council of Tasmania and Cancer Foundation of Western Australia and the NHMRC (199600). ABS is supported by an NHMRC Senior Research Fellowship.The Breakthrough Generations Study investigators thank Breakthrough Breast Cancer and the Institute of Cancer Research (ICR) for support and funding of the Breakthrough Generations Study. The ICR acknowledge NHS funding to the NIHR Biomedical Research Centre.